RO 3201195

Drug Profile

RO 3201195

Alternative Names: RO320-1195

Latest Information Update: 04 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche Palo Alto LLC
  • Developer Roche Palo Alto
  • Class Antirheumatics; Pyrazoles; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 04 Jul 2006 No development reported - Phase-I for Rheumatoid arthritis in USA (unspecified route)
  • 27 Sep 2001 Phase-I clinical trials in Rheumatoid arthritis in USA (unspecified route)
  • 27 Sep 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top